No. | Symbol | Company | Analyst Recommendation / Rating Change | Target Price | Date | Chart |
---|---|---|---|---|---|---|
1 | AINC | Ashford | Rating: Outperform | $28 | 06-14-2022 | View Chart |
2 | CHK | Chesapeake Energy | Rating: Outperform | $115 | 06-14-2022 | View Chart |
3 | CHRS | Coherus BioSciences | Rating: Neutral | $7 | 06-14-2022 | View Chart |
4 | HZNP | Horizon Pharma | Rating: Buy | $139 | 06-14-2022 | View Chart |
5 | ITCI | Intra-Cellular Therapies | Rating: Buy | $75 | 06-14-2022 | View Chart |
6 | JAZZ | Jazz Pharma | Rating: Buy | $194 | 06-14-2022 | View Chart |
7 | LCTX | Lineage Cell Therapeutics | Rating: Buy | $4 | 06-14-2022 | View Chart |
8 | MPC | Marathon Petroleum | Rating: Outperform | $135 | 06-14-2022 | View Chart |
9 | PSX | Phillips 66 | Rating: Outperform | $132 | 06-14-2022 | View Chart |
10 | VLO | Valero Energy | Rating: Market Perform | $155 | 06-14-2022 | View Chart |
11 | VTRS | Viatris | Rating: Sell | $9 | 06-14-2022 | View Chart |
12 | VVI | Viad Corp | Rating: Outperform | $42 | 06-14-2022 | View Chart |
No. | Symbol | Company | Analyst Recommendation / Rating Change | Target Price | Date | Chart |
---|---|---|---|---|---|---|
1 | BBSI | Barrett Business | Rating: Buy | $97 | 06-14-2022 | View Chart |
2 | RPRX | Royalty Pharma | Rating: Buy | $47 | 06-14-2022 | View Chart |
3 | TEVA | Teva Pharma | Rating: Neutral | $10 | 06-14-2022 | View Chart |
No. | Symbol | Company | Analyst Recommendation / Rating Change | Target Price | Date | Chart |
---|---|---|---|---|---|---|
1 | ADBE | Adobe | Rating: Outperform | $600>>500 | 06-14-2022 | View Chart |
2 | DMTK | DermTech | Rating: Buy | $38>>19 | 06-14-2022 | View Chart |
3 | NUE | Nucor | Rating: Neutral | $146>>125 | 06-14-2022 | View Chart |
4 | ORCL | Oracle | Rating: Buy | $126>>113 | 06-14-2022 | View Chart |
5 | SELB | Selecta Biosciences | Rating: Buy | $6>>5 | 06-14-2022 | View Chart |
6 | X | U.S. Steel | Rating: Underweight | $34>>28 | 06-14-2022 | View Chart |